The present disclosure is in the field of ‘pharmacognosy’ and ‘chemistry of natural products’. The present disclosure generally relates to a process of isolation and purification of Biochemical Constituents from algae. The present disclosure particularly relates to a process of isolation and purification of Biochemical Constituents from a biomass of cyanobacteria. The present disclosure provides a process for isolating and extracting phycocyanins, chlorophylls, proteins and polysaccharides from the spirulina biomass.

A method of processing a liquid including adding an antifoam to a process liquid, and after adding the antifoam, continuously feeding the process liquid through one or more cross-flow filter membrane configured for cross-flow filtration, wherein the antifoam includes a mixture of (A) a vegetable oil and (B) an organic emulsifier or surfactant. The antifoam may, for example, not contain silicone.

Embodiments of the present disclosure include systems and methods for enhancing the performance and efficiency of separation processes. The methods include flowing a fluid through a processing zone defined by an antiferromagnetic portion of a conduit and, as the fluid flows through the processing zone, exposing the fluid to a magnetic field produced by oscillating electromagnetic waves, wherein the direction of the magnetic field is generally counter to the direction in which the fluid is flowing. The systems include magnetic treatment units, separation systems, and the like.

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for purifying bacteriophage. Provided herein is are practicable methods, or protocols, that are “Good Laboratory Manufacturing Practice” (GLMP), for phage isolation, selection, liter-scaled cultivation, and purification. In alternative embodiments, GLMP protocols as provided herein employ membrane filtration processes to yield at least about 300 treatment doses at about 10.sup.9 plaque-forming units with endotoxin levels within human therapeutic regulatory limits. In alternative embodiments, provided are formulations or pharmaceutical preparations of bacteriophage comprising 10.sup.9 PFU, 10.sup.10 PFU, 10.sup.11 PFU, or 10.sup.12 PFU or more per unit dose and endotoxin levels below about 5.5 EU.Math.mL.sup.−1, or below about 5.0 EU.Math.mL.sup.−1.

The invention relates generally to methods of improving function of a transplanted organ, treating or preventing primary graft dysfunction of a transplanted organ, treating or preventing acute rejection of a transplanted organ, treating or preventing delayed graft function, or achieving a clinical endpoint indicative of a successful organ transplant in a recipient of the transplanted organ which comprise contacting blood from the recipient with an extracorporeal membrane having a plurality of pores having an average pore size of at least 40 kDa, 50 kDa or 60 kDa to permit inflammatory cytokines and other inflammatory molecules to pass through the pores and out of the blood that is returned back to the recipient.

A method for preparing a durably hydrophilic and uniform-pore ultrafiltration membrane is disclosed herein. Chemical reactions between the functional groups and the active bonds of the molecular chains in the membrane materials are initiated perform the grafting of hydrophilic chains on the polymer chains under conventional dissolution conditions of the polymer membrane material (dissolution with synchronized hydrophilization), so as to realize durable hydrophilization of the membrane materials. The resulting hydrophilized polymer solution (a nascent-state membrane) is introduced into a coagulation bath to initiate a crosslinking reaction among the hydrophilic chains. The resulting crosslinking serves to synergistically regulate subsequent phase separation and membrane formation (phase separation under synergistic crosslinking).

A method of obtaining a compound may include adding a substrate to a medium in a reactor, and reacting the substrate in the reactor to form the compound. A first stream is separated from the reaction liquid through a first membrane. A second stream is separated from the reaction liquid through a second membrane. The first membrane is a filtration membrane and the second membrane is configured for liquid-gas or liquid-liquid extraction The first membrane and the second membrane are at least partially immersed in the medium and are moved relative to the reactor during the separation steps.

The present invention relates to the separation and isolation of neutral human milk oligosaccharides (HMOs) from the reaction mixture in which they are produced.

This disclosure relates generally to process filtration systems, and more particularly to systems utilizing tangential flow filtration.

The present invention relates to: a method of purifying an antibody, which can prepare a desired antibody with high purity and high quality by removing impurities without using an expensive protein A column, and particularly, can purify an antibody in a high yield while greatly reducing an amount (volume) of a buffer used in an elution process; and an antibody prepared by the method.